Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as...
- Mechanism
- Curator reviewed
Dicumarol inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.
- Primary indication
- For decreasing blood clotting.Curator reviewed
- Formula / weight
- C19H12O6 · 336.295 g/mol (avg)
- Also known as
- bis-hydroxycoumarin · Dicumarol
- Code names
- NSC-17860 · NSC-221570 · NSC-41834
Resolves to
DOBMPNYZJYQDGZ-UHFFFAOYSA-NSMILESOC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Dicoumarol, and which of those have an active Phase 3 trial?